ClinicalTrials.gg
CompletedNCT06268301Updated Dec 2, 2024Results posted

A Study to Determine the Effect Food Has on TAK-721 (Budesonide Oral Suspension) in the Body of Healthy Adults

A Phase 1 interventional study of Budesonide in Healthy Volunteers, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-02.

Sponsored by Takeda · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Feb 2023, registered Feb 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Study summary

The main aim of this study is to check what the body of a healthy adult who either fasted or had eaten does to TAK-721 and how TAK-721 is distributed in and removed from the body. Other aims are to learn how safe the treatment with TAK-721 is and how suitable the TAK-721 is for healthy adults who either fasted or had eaten. All participants will receive TAK-721 but half will be assigned by chance to the participant group who are fasting first then getting the high-fat/high-calorie meal later or the group who gets meal first and fasts later. The group assignment will be switched once during the course of the study so that all participants will receive TAK-721 in both a fasted or fed condition.

Read the detailed description

The drug being tested in this study is called budesonide. Budesonide oral suspension (BOS) is being tested in healthy adult participants. This study will determine whether the absorption of BOS will be altered if taken with food.

The study will enroll approximately 20 patients. The study will consist of two treatment sequences and two periods separated by a washout period of 2 days. Participants will be randomly assigned (by chance, like flipping a fair coin) to one of the two treatment sequences:

  • Treatment Sequence 1: Participants will receive 2 mg BOS orally on Day 1 of Period 1 in fasted condition (Treatment A). Two days later, participants will receive 2 mg BOS orally on Day 1 of Period 2 in fed condition (Treatment B).
  • Treatment Sequence 2: Participants will receive 2 mg BOS orally on Day 1 of Period 1 in fed condition (Treatment B). Two days later, participants will receive 2 mg BOS orally on Day 1 of Period 2 in fasted condition (Treatment A).

This single center trial will be conducted in the United States. Participation in the study is up to approximately 34 days. Participants will visit the clinic approximately three days after last dose of study drug for a follow-up assessment.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Drug therapy
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to the first dosing based on participant self-reporting.
  2. (BMI) ≥ 18.0 and ≤ 32.0 kilograms per meters squared (kg/m\^2) at the screening visit.

Exclusion criteria

Exclusion Criteria:

  1. Presence of any active infection at the screening visit or check-in.
  2. Positive urine drug or alcohol results at the screening visit or check-in.
  3. Positive results for (HIV), surface antigen (HBsAg), or virus (HCV) at the screening visit.
  4. Participant is unable to refrain from or anticipates the use of:

    1. Any drugs, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to the first dosing. Medication listed as part of acceptable methods, hormone replacement therapy, and thyroid hormone replacement medication will be allowed.
    2. Any drugs known to be moderate or strong inducers of cytochrome P450 (CYP) 3A4 enzymes and/or p-glycoprotein (P-gp), including St. John's Wort, for 28 days prior to the first dosing. Appropriate sources (e.g., Flockhart Table™) will be consulted to confirm lack of pharmacokinetic (PK) /pharmacodynamic interaction with the study drug.
  5. Participant is lactose intolerant.
  6. Donation of blood or significant blood loss within 56 days prior to the first dosing.
  7. Plasma donation within 7 days prior to the first dosing.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Sequence 1: BOS 2 mg Fasted, then Fed

    Participants will receive 2 mg BOS, single dose, orally on Day 1 of Period 1 under fasted condition (Treatment A). Two days later, participants will receive 2 mg BOS single dose, orally on Day 1 of Period 2 under fed condition (Treatment B).

    Drug: Budesonide

  • Experimental
    Sequence 2: BOS 2 mg Fed, then Fasted

    Participants will receive 2 mg BOS, single dose, orally on Day 1 of Period 1 under fed condition (Treatment B). Two days later, participants will receive 2 mg BOS single dose, orally on Day 1 of Period 2 under fasted condition (Treatment A).

    Drug: Budesonide

Interventions

  • Budesonide oral suspension

    Also known as: TAK-721

06

What researchers measure

Primary outcomes

  1. Maximum Observed Concentration (Cmax) of BOS

    Time frame: Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1

  2. Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of BOS

    Time frame: Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1

  3. Area Under the Concentration-time Curve From Time 0 to Infinity (AUC∞) of BOS

    Time frame: Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1

Secondary outcomes

  1. Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE), Serious Adverse Events (SAE), and Death

    An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE was defined as an adverse event with an onset that occurs after receiving study drug. An SAE was defined as any untoward medical occurrence that at any dose results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that may require an intervention to prevent above items and expose the participant to danger.

    Time frame: From first dose of study drug up to the end of study (EOS) (Up to 15 days)

  2. Number of Participants With Clinically Significant Abnormal Vital Sign Values Reported as Adverse Events

    Vital signs included body temperature, respiratory rate, blood pressure, and pulse rate evaluations.

    Time frame: From first dose of study drug up to EOS (Up to 15 days)

  3. Number of Participants With Clinically Significant Abnormal Clinical Laboratory Values Reported as Adverse Events

    Clinical laboratory parameters included hematology, clinical chemistry, serum immunoglobulin and urinalysis tests.

    Time frame: From first dose of study drug up to EOS (Up to 15 days)

  4. Area Under the Concentration-time Curve From Time 0 to 12 Hours (AUC0-12) of BOS

    Time frame: Periods 1 and 2: Pre-dose and at multiple timepoints (up to 12 hours) post-dose on Day 1

  5. Area Under the Curve From the Last Quantifiable Concentration to Infinity Expressed as a Percentage of AUC∞ (AUCextrap%) of BOS

    Time frame: Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1

  6. Time to First Occurrence of Cmax (Tmax) of BOS

    Time frame: Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1

  7. Lag Time to First Quantifiable Concentration (Tlag) of BOS

    Time frame: Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1

  8. Terminal Disposition Phase Half-life (t1/2z) of BOS

    Time frame: Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1

  9. Terminal Disposition Phase Rate Constant (λz) of BOS

    Time frame: Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1

  10. Apparent Clearance (CL/F) of BOS Calculated Using the Observed Value of the Last Quantifiable Concentration of BOS

    Time frame: Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1

  11. Apparent Volume of Distribution During the Terminal Disposition Phase (Vz/F) of BOS Calculated Using the Observed Value of the Last Quantifiable Concentration of BOS

    Time frame: Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1

07

Results

Posted Dec 2, 2024

Participant flow

Participants took part in the study at 1 investigative site in the United States from 6 February 2023 to 20 February 2023.

Period 1
Participant flow — Period 1
MilestoneSequence 1: BOS 2 mg Fasted, Then FedSequence 2: BOS 2 mg Fed, Then Fasted
Started1010
Completed1010
Not completed00
Period 2
Participant flow — Period 2
MilestoneSequence 1: BOS 2 mg Fasted, Then FedSequence 2: BOS 2 mg Fed, Then Fasted
Started1010
Completed1010
Not completed00

Outcome measures

PrimaryMaximum Observed Concentration (Cmax) of BOS
Time frame:
Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1
Reported as:
Geometric mean · picograms per milliliter (pg/mL)
Maximum Observed Concentration (Cmax) of BOS
picograms per milliliter (pg/mL)Treatment A: BOS 2 mg FastedTreatment B: BOS 2 mg Fed
Maximum Observed Concentration (Cmax) of BOS692.9 ± 54.4604.1 ± 46.6
PrimaryArea Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of BOS
Time frame:
Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1
Reported as:
Geometric mean · picograms*hours per milliliter (pg*h/mL)
Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of BOS
picograms*hours per milliliter (pg*h/mL)Treatment A: BOS 2 mg FastedTreatment B: BOS 2 mg Fed
Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of BOS2811 ± 57.53529 ± 52.1
PrimaryArea Under the Concentration-time Curve From Time 0 to Infinity (AUC∞) of BOS
Time frame:
Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1
Reported as:
Geometric mean · pg*h/mL
Area Under the Concentration-time Curve From Time 0 to Infinity (AUC∞) of BOS
pg*h/mLTreatment A: BOS 2 mg FastedTreatment B: BOS 2 mg Fed
Area Under the Concentration-time Curve From Time 0 to Infinity (AUC∞) of BOS3075 ± 57.03892 ± 47.1
SecondaryNumber of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE), Serious Adverse Events (SAE), and Death

An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE was defined as an adverse event with an onset that occurs after receiving study drug. An SAE was defined as any untoward medical occurrence that at any dose results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that may require an intervention to prevent above items and expose the participant to danger.

Time frame:
From first dose of study drug up to the end of study (EOS) (Up to 15 days)
Reported as:
Count of participants · Participants
Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE), Serious Adverse Events (SAE), and Death
ParticipantsTreatment A: BOS 2 mg FastedTreatment B: BOS 2 mg Fed
TEAEs25
SAEs00
Deaths00
SecondaryNumber of Participants With Clinically Significant Abnormal Vital Sign Values Reported as Adverse Events

Vital signs included body temperature, respiratory rate, blood pressure, and pulse rate evaluations.

Time frame:
From first dose of study drug up to EOS (Up to 15 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormal Vital Sign Values Reported as Adverse Events
ParticipantsTreatment A: BOS 2 mg FastedTreatment B: BOS 2 mg Fed
Number of Participants With Clinically Significant Abnormal Vital Sign Values Reported as Adverse Events00
SecondaryNumber of Participants With Clinically Significant Abnormal Clinical Laboratory Values Reported as Adverse Events

Clinical laboratory parameters included hematology, clinical chemistry, serum immunoglobulin and urinalysis tests.

Time frame:
From first dose of study drug up to EOS (Up to 15 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormal Clinical Laboratory Values Reported as Adverse Events
ParticipantsTreatment A: BOS 2 mg FastedTreatment B: BOS 2 mg Fed
Number of Participants With Clinically Significant Abnormal Clinical Laboratory Values Reported as Adverse Events00
SecondaryArea Under the Concentration-time Curve From Time 0 to 12 Hours (AUC0-12) of BOS
Time frame:
Periods 1 and 2: Pre-dose and at multiple timepoints (up to 12 hours) post-dose on Day 1
Reported as:
Geometric mean · pg*h/mL
Area Under the Concentration-time Curve From Time 0 to 12 Hours (AUC0-12) of BOS
pg*h/mLTreatment A: BOS 2 mg FastedTreatment B: BOS 2 mg Fed
Area Under the Concentration-time Curve From Time 0 to 12 Hours (AUC0-12) of BOS2728 ± 53.03208 ± 42.2
SecondaryArea Under the Curve From the Last Quantifiable Concentration to Infinity Expressed as a Percentage of AUC∞ (AUCextrap%) of BOS
Time frame:
Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1
Reported as:
Geometric mean · percentage of AUC
Area Under the Curve From the Last Quantifiable Concentration to Infinity Expressed as a Percentage of AUC∞ (AUCextrap%) of BOS
percentage of AUCTreatment A: BOS 2 mg FastedTreatment B: BOS 2 mg Fed
Area Under the Curve From the Last Quantifiable Concentration to Infinity Expressed as a Percentage of AUC∞ (AUCextrap%) of BOS7.275 ± 61.77.126 ± 75.6
SecondaryTime to First Occurrence of Cmax (Tmax) of BOS
Time frame:
Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1
Reported as:
Median · hours (h)
Time to First Occurrence of Cmax (Tmax) of BOS
hours (h)Treatment A: BOS 2 mg FastedTreatment B: BOS 2 mg Fed
Time to First Occurrence of Cmax (Tmax) of BOS1.286 (0.55 to 2.57)2.516 (1.01 to 6.03)
SecondaryLag Time to First Quantifiable Concentration (Tlag) of BOS
Time frame:
Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1
Reported as:
Median · hours
Lag Time to First Quantifiable Concentration (Tlag) of BOS
hoursTreatment A: BOS 2 mg FastedTreatment B: BOS 2 mg Fed
Lag Time to First Quantifiable Concentration (Tlag) of BOS0.328 (0.26 to 0.56)0.308 (0.25 to 0.53)
SecondaryTerminal Disposition Phase Half-life (t1/2z) of BOS
Time frame:
Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1
Reported as:
Median · hours
Terminal Disposition Phase Half-life (t1/2z) of BOS
hoursTreatment A: BOS 2 mg FastedTreatment B: BOS 2 mg Fed
Terminal Disposition Phase Half-life (t1/2z) of BOS4.270 (2.13 to 6.98)5.096 (2.78 to 7.35)
SecondaryTerminal Disposition Phase Rate Constant (λz) of BOS
Time frame:
Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1
Reported as:
Median · 1/hour
Terminal Disposition Phase Rate Constant (λz) of BOS
1/hourTreatment A: BOS 2 mg FastedTreatment B: BOS 2 mg Fed
Terminal Disposition Phase Rate Constant (λz) of BOS0.1627 (0.0994 to 0.325)0.1362 (0.0943 to 0.249)
SecondaryApparent Clearance (CL/F) of BOS Calculated Using the Observed Value of the Last Quantifiable Concentration of BOS
Time frame:
Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1
Reported as:
Geometric mean · liters per hour (L/h)
Apparent Clearance (CL/F) of BOS Calculated Using the Observed Value of the Last Quantifiable Concentration of BOS
liters per hour (L/h)Treatment A: BOS 2 mg FastedTreatment B: BOS 2 mg Fed
Apparent Clearance (CL/F) of BOS Calculated Using the Observed Value of the Last Quantifiable Concentration of BOS650.4 ± 57.0513.9 ± 47.1
SecondaryApparent Volume of Distribution During the Terminal Disposition Phase (Vz/F) of BOS Calculated Using the Observed Value of the Last Quantifiable Concentration of BOS
Time frame:
Periods 1 and 2: Pre-dose and at multiple timepoints (up to 24 hours) post-dose on Day 1
Reported as:
Geometric mean · liters (L)
Apparent Volume of Distribution During the Terminal Disposition Phase (Vz/F) of BOS Calculated Using the Observed Value of the Last Quantifiable Concentration of BOS
liters (L)Treatment A: BOS 2 mg FastedTreatment B: BOS 2 mg Fed
Apparent Volume of Distribution During the Terminal Disposition Phase (Vz/F) of BOS Calculated Using the Observed Value of the Last Quantifiable Concentration of BOS3967 ± 45.03513 ± 32.9

Adverse events

Collected over From first dose of study drug up to the EOS (15 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A: BOS 2 mg Fasted0/20 (0%)0/20 (0%)2/20 (10%)
Treatment B: BOS 2 mg Fed0/20 (0%)0/20 (0%)5/20 (25%)
Most frequent other events
Most frequent other events
EventTreatment A: BOS 2 mg FastedTreatment B: BOS 2 mg Fed
Vessel puncture site painGeneral disorders0/202/20
HeadacheNervous system disorders2/201/20
DiarrhoeaGastrointestinal disorders0/201/20
Vessel puncture site bruiseGeneral disorders0/201/20
Vessel puncture site swellingGeneral disorders0/201/20
Musculoskeletal chest painMusculoskeletal and connective tissue disorders1/200/20

Baseline characteristics

Safety Set included all participants who received any study drug.

Age, Continuous
Age, Continuous(years)Sequence 1: BOS 2 mg Fasted, Then FedSequence 2: BOS 2 mg Fed, Then FastedTotal
Mean38.6 ± 9.5032.7 ± 9.9735.7 ± 9.95
Sex: Female, Male
Sex: Female, Male(Participants)Sequence 1: BOS 2 mg Fasted, Then FedSequence 2: BOS 2 mg Fed, Then FastedTotal
Female7512
Male358
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sequence 1: BOS 2 mg Fasted, Then FedSequence 2: BOS 2 mg Fed, Then FastedTotal
Hispanic or Latino213
Not Hispanic or Latino8917
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sequence 1: BOS 2 mg Fasted, Then FedSequence 2: BOS 2 mg Fed, Then FastedTotal
American Indian or Alaska Native101
Asian202
Native Hawaiian or Other Pacific Islander000
Black or African American123
White5611
More than one race123
Unknown or Not Reported000
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms per metre square (kg/m^2))Sequence 1: BOS 2 mg Fasted, Then FedSequence 2: BOS 2 mg Fed, Then FastedTotal
Mean27.52 ± 2.91027.59 ± 2.70627.56 ± 2.735
Height
Height(centimetres (cm))Sequence 1: BOS 2 mg Fasted, Then FedSequence 2: BOS 2 mg Fed, Then FastedTotal
Mean165.4 ± 10.71169.0 ± 11.52167.2 ± 10.98
Weight
Weight(kilograms (kg))Sequence 1: BOS 2 mg Fasted, Then FedSequence 2: BOS 2 mg Fed, Then FastedTotal
Mean75.99 ± 15.3979.51 ± 14.5377.75 ± 14.68
08

Study locations

1 site
  • Celerion
    Lincoln, Nebraska 68502, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in Feb 2023, 0 months.

Results were first posted in Dec 2024, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2024
First posted
Feb 20, 2024
StartActual
Feb 6, 2023
Primary completionActual
Feb 17, 2023
CompletionActual
Feb 20, 2023
Results first posted
Dec 2, 2024
Last update
Dec 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06268301
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Feb 20, 2024
Start date
Feb 6, 2023
Primary completion
Feb 17, 2023
Completion
Feb 20, 2023
Results posted
Dec 2, 2024
Last update
Dec 2, 2024

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion